Pfizer Settles Foreign Bribery Charges, Wins Deferred Prosecution For Helping Government
This article was originally published in PharmAsia News
Executive Summary
Pfizer reaches separate settlements with U.S. DoJ and SEC to resolve charges its subsidiaries bribed Chinese, Russian and other foreign government officials; a subsidiary enters a deferred prosecution agreement with DoJ.
You may also be interested in...
DoJ Bull’s Eye: Off-Label Promotion, Formulary Placements, FCPA Violations Remain Targets
A Pfizer attorney says government saber rattling over individual liability does not mean there will be a spike in individual prosecutions; Pfizer’s cooperation with the government helped it avoid criminal resolution in a Foreign Corrupt Practices Act settlement.
J&J Takes The Lead In Settling SEC/DoJ Foreign Corrupt Practices Act Probe
Johnson & Johnson agreed to pay $70 million to resolve charges by the Securities and Exchange Commission and the Department of Justice that the company bribed doctors in several European countries to order or prescribe its products in violation of the Foreign Corrupt Practices Act
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.